FSD: Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human MS Trial

 FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced completion of the first-in-human (“FIH”) sentinel dosing of Lucid-21-302 (“Lucid-MS”) in the Company’s Phase I clinical trial evaluating its novel drug candidate as an orally-administered treatment for Multiple Sclerosis (“MS”). The sentinel dose was completed on Sunday, April 16, 2023.

https://www.biospace.com/article/releases/fsd-pharma-achieves-milestone-in-completion-of-dosing-of-sentinel-subjects-in-first-in-human-clinical-trial-of-lucid-ms-lucid-21-302-for-multiple-sclerosis/